PETALING JAYA: There has been a 150% increase in patient arrivals at the country's Covid-19 Assessment Centres (CAC), which were designed to help manage patients who are undergoing home treatment.
PETALING JAYA: Malaysia will participate in phase three clinical trials for a new vaccine manufactured by Chinese firm Shenzhen Kangtai Biological Products Co Ltd, says the Health Ministry.
Health director-general Tan Sri Dr Noor Hisham Abdullah said the clinical study involving the inactivated vaccine was approved by the National Pharmaceutical Regulatory Agency (NPRA) on May 28.
Phase three clinical study of this vaccine will be conducted in eight research centres in Malaysia targeting the participation of 3,000 adults aged 18 years and above and is expected to take 15 to 19 months. The Health Ministry would like to inform that there is an addition of one clinical study, involving the product SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL manufactured by Shenzhen Kangtai Biological Products Co Ltd from China.
KUALA LUMPUR (Bernama): The Health Ministry and the Institute for Clinical Research (ICR) have started clinical trials to study the use and efficacy of Ivermectin for high-risk Covid-19 patients at 12 of the ministry's hospitals.